Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Metformin in Head and Neck Squamous Cell Carcinoma
NCT03618654Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2018
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs) in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Immune cell polarization (Th1/Th2; M1/M2) up to 6 months. Started Nov 2018; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03618654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618654.